Tonix Pharmaceuticals Holding Corp. (TNXP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 10M 20M 30M Q2 '24: 12.5M Q3 '24: 11.3M Q4 '24: 10.1M Q1 '25: 10M Q2 '25: 9.8M Q3 '25: 10.3M Q4 '25: 13.1M Q1 '26: 17.6M Q2 '26: 29.1M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

0 9M 18M 27M Q2 '24: 2.7M Q3 '24: 2.3M Q4 '24: 2.3M Q1 '25: 3M Q2 '25: 2.9M Q3 '25: 3.5M Q4 '25: 6.5M Q1 '26: 10.3M Q2 '26: 24.4M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -79.9M Q4 '21: -92.3M Q1 '22: -98M Q2 '22: -97.8M Q3 '22: -108.8M Q4 '22: -112.1M Q1 '23: -119.6M Q2 '23: -125.2M Q3 '23: -123.8M Q4 '23: -118.4M Q1 '24: -105.8M Q2 '24: -154.1M Q3 '24: -141.6M Q4 '24: -136.7M Q1 '25: -131.4M Q2 '25: -82.4M Q3 '25: -99.9M Q4 '25: -125.7M Q1 '26: -151.2M Q2 '26: -165.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -79.8M Q4 '21: -92.3M Q1 '22: -98.1M Q2 '22: -97.6M Q3 '22: -108.1M Q4 '22: -110.2M Q1 '23: -116.8M Q2 '23: -122M Q3 '23: -121M Q4 '23: -116.7M Q1 '24: -98.6M Q2 '24: -149M Q3 '24: -135.2M Q4 '24: -130M Q1 '25: -131.9M Q2 '25: -81.4M Q3 '25: -99.2M Q4 '25: -124M Q1 '26: -147.4M Q2 '26: -159.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 3.5M 7M 10.5M Q2 '24: 9.8M Q3 '24: 8.9M Q4 '24: 7.8M Q1 '25: 7M Q2 '25: 7M Q3 '25: 6.8M Q4 '25: 6.6M Q1 '26: 7.3M Q2 '26: 4.7M Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -67M Q4 '21: -75.6M Q1 '22: -85.5M Q2 '22: -87.6M Q3 '22: -98.2M Q4 '22: -98.1M Q1 '23: -99.9M Q2 '23: -102.1M Q3 '23: -102M Q4 '23: -102M Q1 '24: -86.7M Q2 '24: -73.2M Q3 '24: -68.6M Q4 '24: -60.9M Q1 '25: -59.9M Q2 '25: -64.8M Q3 '25: -74.8M Q4 '25: -99.8M Q1 '26: -125.6M Q2 '26: -153M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -81.2M Q4 '21: -110.9M Q1 '22: -140.6M Q2 '22: -155.6M Q3 '22: -167.3M Q4 '22: -146.2M Q1 '23: -131.6M Q2 '23: -121.2M Q3 '23: -114.1M Q4 '23: -109.9M Q1 '24: -90.9M Q2 '24: -75.6M Q3 '24: -69.2M Q4 '24: -61M Q1 '25: -59.9M Q2 '25: -65.4M Q3 '25: -76.3M Q4 '25: -103.2M Q1 '26: -130.6M Q2 '26: -158.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q1 '21: 290.1M Q2 '21: 10.5M Q3 '21: 11.6M Q1 '22: 16.4M Q2 '22: 3.6M Q3 '22: 6.8M Q1 '23: 10.3M Q2 '23: 576K Q3 '23: 724.2K Q1 '24: 27.9K Q2 '24: 41K Q3 '24: 626.7K Q1 '25: 5.9M Q2 '25: 7.3M Q3 '25: 8.9M Q1 '26: 13.7M Q2 '26: 16.6M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18000.00 -12000.00 -6000.00 0.00 6000.00 12000.00 18000.00 Q3 '20: 7.85 Q4 '20: -0.75 Q1 '21: -0.45 Q2 '21: -2.47 Q3 '21: -3.98 Q4 '21: -6.00 Q1 '22: -7.54 Q2 '22: -12.93 Q3 '22: -15.57 Q4 '22: -14.92 Q1 '23: -16.52 Q2 '23: -58.11 Q3 '23: -92.50 Q4 '23: -14667.85 Q1 '24: -15200.36 Q2 '24: -17071.98 Q3 '24: -17056.03 Q4 '25: -14.44 Q1 '26: -14.53 Q2 '26: -13.11 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.